Chronic Low Back Pain Clinical Trial
Official title:
A Case Series Evaluation of Psychodynamic Interpersonal Therapy (PIT) in Chronic Low Back Pain (CLBP) Patients
Verified date | September 2019 |
Source | University of Manchester |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Many people in the world have chronic pain; this is pain which lasts more than twelve weeks.
Pain can cause people to feel low in mood and change how they feel about themselves and
others around them. Therapy for chronic pain does not always work and often people do not
have lasting effects from treatment. This study hopes to see if a different therapy, called
Psychodynamic Interpersonal Therapy (PIT), can help people with chronic pain. This therapy
looks at how we see ourselves and our relationships with others; it aims to help people
address personal problems that make it difficult for them to manage their pain.
The study aims to show that PIT is a suitable treatment for chronic low back pain and that
people will have fewer problems with their mood, how they feel about themselves and their
relationships. This study will give people with chronic low back pain eight sessions of PIT
and during therapy they will fill in forms about their pain, mood, relationship problems and
how they feel about themselves. We will also look at practical things to do with the therapy
(e.g. how many sessions people came to, reasons for stopping therapy etc.) and ask people
about how they felt about the therapy they had. Three months after the study has finished,
people will be asked to fill in the forms again to see if the effects have lasted.
This research could help to give people with chronic pain a new and different treatment
option which has good and lasting effects.
Status | Completed |
Enrollment | 8 |
Est. completion date | September 9, 2019 |
Est. primary completion date | March 29, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Previously attended the Walton Centre pain management programme (PMP). - Treatment resistant; six months after PMP treatment still experiencing clinically significant pain measured as 5+ on the pain distress rating scale. IMMPACT recommendations advise the use of numerical rating scales (NRS) in clinical trials of chronic pain treatments (Dworkin et al., 2005). - Classified as "interpersonally distressed" on the West Haven Yale Multidimensional Pain Inventory (WHYMPI). - Able to converse in English proficiently which is a requirement given the conversational nature of therapy. - Able to commit to treatment and willing to be randomly allocated to baseline. Exclusion Criteria: - Other comorbid degenerative conditions and cancers. - Psychosis - History of prior suicide attempts. - Active plans of self-harm and/or suicide. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | The Walton Centre NHS Foundation Trust | Liverpool |
Lead Sponsor | Collaborator |
---|---|
Charlotte Morgan |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective measure of behaviour 1 - Number of sessions attended | Measuring feasibility/acceptability of therapy | Measured at the end of therapy (at week 8). | |
Primary | Satisfaction questionnaire (PIT for CLBP) | Measuring acceptability of therapy (face validity). A self-reported measure of satisfaction regarding the content of the therapy. A questionnaire has been devised based on the theoretical framework of acceptability in Sekon, Cartwright & Francis (2017). There are two versions for post session one and post session eight with slightly different wording. This outcome measure will assess change. | Administered twice in the 8 weeks of therapy after session 1 (week 1) and Session 8 (week 8); the first and last sessions of therapy. | |
Primary | Measure of adverse reactions | A quantitative measure containing a list of anticipated/likely adverse reactions (e.g. exacerbation of pain, feeling more upset than usual, increased problems in relationships) and unanticipated/adverse reactions. It is expected that therapy may increase emotional symptoms in the short term as the participants make realisations within therapy. This is a tick box measure with a qualitative 'other' box for further input.This outcome measure will assess change. | Participants will complete this before each therapy session weekly and it will be discussed with the therapist/PI in session. As therapy is for 8 weeks, participants will complete this once weekly for eight weeks. | |
Primary | Objective measure of behaviour 2 - Completion rate from therapy | Measuring feasibility/acceptability of therapy | Measured at the end of therapy (at week 8). | |
Secondary | Chronic Pain Acceptance Questionnaire-8 (CPAQ-8) | CPAQ-8 - Fish, R. A., McGuire, B., Hogan, M., et al. (2010) A short version of the CPAQ and consists of eight items which measures pain acceptance and distress. | During baseline (no therapy) this will be completed weekly for a minimum of 3 weeks and a maximum of 6 weeks (dependent on randomised baseline group). All participants will complete the measure weekly during therapy for 8 weeks. | |
Secondary | Pain Self Efficacy Questionnaire (PSEQ) | PSEQ Nicholas, M. K (2007). The PSEQ assesses confidence in performing activities whilst in pain and beliefs about coping with pain. | During baseline (no therapy) this will be completed weekly for a minimum of 3 weeks and a maximum of 6 weeks (dependent on randomised baseline group). All participants will complete the measure weekly during therapy for 8 weeks. | |
Secondary | The Interpersonal Needs Questionnaire for Pain (INQ-P) | INQ-P (Methley et al. 2017). A measure of interpersonal factors in chronic pain adapted from the INQ; assesses thwarted belongingness and perceived burdensomeness specific to chronic pain. | During baseline (no therapy) this will be completed weekly for a minimum of 3 weeks and a maximum of 6 weeks (dependent on randomised baseline group). All participants will complete the measure weekly during therapy for 8 weeks. | |
Secondary | The Beck Depression Inventory (BDI) | BDI (Beck et al. 1961). The BDI is recommended as a core outcome measure of emotional functioning in chronic pain clinical trials (Dworkin at al., 2005). | During baseline (no therapy) this will be completed weekly for a minimum of 3 weeks and a maximum of 6 weeks (dependent on randomised baseline group). All participants will complete the measure weekly during therapy for 8 weeks. | |
Secondary | Daily clinical measure (4 questions) | Four single item measures were generated using literature on interpersonal difficulties in chronic pain. All questions may be scored from 0-5; 0 being 'Not at all' and 5 being ' As good as I can feel/Extremely'. "How distressing has your pain been today?" "How lonely have you felt today?" "How good have you felt about your relationships with other people today?" "How good have you felt about yourself today?" Item 1 is based on generic numerical rating scales used to measure pain distress. Item 2 is a measure of social distress that we would expect to be amenable to change via PIT; it is an important outcome that overlaps with but is not the same as depression. Items 3 and 4 measure variables that PIT is designed to target and which we might expect to mediate any improvement in the other outcomes. Item 3 links with social connection (i.e., belongingness) and item 4 with perceived burdensomeness since how you feel about yourself influences whether you see yours. |
During baseline (no therapy) answered daily for a minimum of 3 weeks and a maximum of 6 weeks (dependent on randomised baseline group). All participants will answer them daily during therapy for 8 weeks. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03243084 -
Transcranial Alternating Current Stimulation in Back Pain- Pilot Sudy
|
N/A | |
Suspended |
NCT04735185 -
Stem Cells vs. Steroids for Discogenic Back Pain
|
N/A | |
Completed |
NCT03162952 -
RAND Center of Excellence for the Study of Appropriateness of Care in CAM
|
||
Completed |
NCT03240146 -
Pulsed Shortwave Therapy Treatment for Chronic Musculoskeletal Low Back Pain
|
N/A | |
Completed |
NCT05282589 -
Lumbopelvic Manipulation Effects on Fatigue in Chronic Low Back Pain Patients
|
N/A | |
Completed |
NCT03637998 -
Physical Activity on Neurophysiologic Gene Expression Profiles of Chronic Low Back Pain
|
N/A | |
Recruiting |
NCT02289170 -
Clinical Study to Evaluate the Safety and Efficacy of Heating and Cooling Combination Therapeutic Device(OCH-S100)
|
N/A | |
Active, not recruiting |
NCT01944163 -
The IMPACT of a Referral Model for Axial Spondyloarthritis in Young Patients With Chronic Low Back Pain
|
N/A | |
Completed |
NCT02231554 -
Feldenkrais vs Back School for Treating Chronic Low Back Pain: a Randomized Controlled Trial
|
N/A | |
Recruiting |
NCT02063503 -
Identification of Prognostic Indicators for Rehabilitation in Chronic Nonspecific Low Back Pain Patients
|
N/A | |
Terminated |
NCT01620775 -
MR(Magnetic Resonance) Imaging of Neurotransmitters in Chronic Pain
|
N/A | |
Completed |
NCT01704677 -
Lumbar Disc Prosthesis Versus Multidisciplinary Rehabilitation; 8-year Follow-up
|
N/A | |
Completed |
NCT01177254 -
Exposure to Potential Cytochrome P450 Pharmacokinetic Drug-Drug Interactions Among Osteoarthritis Patients: Incremental Risk of Multiple Prescriptions
|
N/A | |
Completed |
NCT01177280 -
Prevalence of Potential Cytochrome P450 Pharmacokinetic Incident Drug-Drug Interactions Among Chronic Low Back Pain Patients Taking Opioid Analgesics and Associated Economic Outcomes
|
N/A | |
Completed |
NCT01177241 -
Cytochrome P450 Pharmacokinetic DDIs Among Patients With Chronic Low Back Pain Taking Opioids
|
N/A | |
Completed |
NCT01490905 -
A Double Blind Placebo Study to Determine the Effectiveness of Theramine on the Management of Chronic Back Pain
|
Phase 4 | |
Completed |
NCT00984815 -
Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment
|
Phase 3 | |
Completed |
NCT00761150 -
Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)
|
Phase 3 | |
Completed |
NCT00763321 -
Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)
|
Phase 3 | |
Completed |
NCT00767806 -
A Study for Patient With Chronic Low Back Pain
|
Phase 3 |